Profile data is unavailable for this security.
About the company
Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
- Revenue in EUR (TTM)809.67m
- Net income in EUR7.74m
- Incorporated1968
- Employees2.91k
- LocationGuerbet SA15 rue des Vanesses, Zone Paris Nord IIVILLEPINTE 93420FranceFRA
- Phone+33 145915000
- Fax+33 145915199
- Websitehttps://www.guerbet.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Medical Systems SA | 46.77m | -1.67m | 36.65m | 140.00 | -- | 2.29 | 40.40 | 0.7835 | -0.069 | -0.069 | 2.05 | 0.6006 | 0.876 | 1.84 | 4.52 | 324,798.60 | -2.86 | -11.47 | -5.81 | -20.52 | 39.79 | 38.72 | -3.27 | -14.95 | 0.6154 | -0.5203 | 0.5811 | -- | 9.29 | 8.24 | 70.50 | -- | -- | -- |
| Theraclion SA | 1.90m | -5.25m | 37.24m | 33.00 | -- | -- | -- | 19.57 | -0.1127 | -0.1127 | 0.0408 | -0.0548 | 0.1479 | 0.3304 | 8.74 | 59,455.31 | -40.84 | -33.44 | -55.80 | -47.33 | 54.01 | 66.95 | -276.15 | -360.91 | 1.79 | -67.33 | 2.50 | -- | -54.44 | -21.49 | -56.66 | -- | -4.97 | -- |
| AbL Diagnostics SA | 5.45m | 463.37k | 54.15m | 20.00 | 116.75 | 7.80 | 44.96 | 9.94 | 0.0288 | 0.0288 | 0.3383 | 0.4308 | 0.4416 | -- | 1.60 | 286,763.20 | 3.76 | 3.59 | 5.34 | 5.29 | -- | -- | 8.50 | 8.20 | 2.91 | -- | 0.2788 | -- | -5.03 | -- | 424.60 | -- | -- | -- |
| Median Technologies SA | 23.31m | -21.99m | 157.15m | 211.00 | -- | -- | -- | 6.74 | -1.16 | -1.16 | 1.23 | -2.08 | 0.8894 | -12.98 | 3.92 | 96,717.84 | -83.91 | -60.70 | -- | -232.35 | 102.73 | 102.32 | -94.35 | -97.73 | 0.3543 | -26.56 | -- | -- | 3.25 | 20.72 | -9.83 | -- | 43.77 | -- |
| Guerbet SA | 809.67m | 7.74m | 171.92m | 2.91k | 33.46 | 0.4557 | 2.44 | 0.2123 | 0.4064 | 0.4064 | 64.25 | 29.85 | 0.7865 | 0.546 | 4.90 | 278,715.70 | 0.4619 | 0.92 | 0.6055 | 1.20 | 78.03 | 76.51 | 0.5873 | 1.19 | 1.03 | 1.46 | 0.5172 | 64.79 | 7.05 | 0.5853 | -32.61 | -15.50 | -0.8569 | -- |
| Affluent Medical SAS | 4.12m | -14.74m | 231.05m | 76.00 | -- | 7.27 | -- | 56.11 | -0.3759 | -0.3759 | 0.1051 | 0.5365 | 0.0709 | -- | 0.9541 | 59,681.16 | -25.40 | -23.76 | -32.61 | -27.59 | 1.34 | -226.93 | -358.01 | -1,815.40 | -- | -924.30 | 0.5030 | -- | -- | -- | 5.84 | -- | -- | -- |
| Lumibird SA | 215.95m | 10.73m | 503.26m | 1.07k | 46.91 | 2.52 | 16.54 | 2.33 | 0.4775 | 0.4775 | 9.61 | 8.90 | 0.5077 | 0.9593 | 4.42 | 202,198.50 | 2.52 | 2.51 | 3.11 | 3.17 | 63.89 | 61.89 | 4.97 | 4.90 | 1.64 | 3.16 | 0.4583 | 0.00 | 1.75 | 13.34 | -20.08 | -8.38 | 15.27 | -- |
| Holder | Shares | % Held |
|---|---|---|
| DNCA Finance SAas of 31 Mar 2025 | 147.93k | 1.17% |
| HMG Finance SAas of 31 Dec 2025 | 115.76k | 0.92% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 106.43k | 0.84% |
| HC Capital Advisors GmbHas of 31 Oct 2025 | 91.68k | 0.73% |
| Twenty First Capital SASas of 30 Jun 2025 | 82.50k | 0.65% |
| Atle Fund Management ABas of 31 Dec 2024 | 79.00k | 0.63% |
| Financi�re Tiepolo SASas of 31 Dec 2024 | 68.00k | 0.54% |
| Quaero Capital SAas of 30 Jun 2025 | 66.95k | 0.53% |
| KBC Asset Management NVas of 30 Jun 2025 | 59.45k | 0.47% |
| Kirao SASas of 28 Jun 2024 | 43.55k | 0.35% |
